Report Reveals U.S. Export Rules Bar Shipping Vaccines To Five Nations
This article was originally published in PharmAsia News
Executive Summary
U.S. export regulations have been revealed to bar vaccines from being sent from the United States to five countries on grounds they export terrorism. Indonesia's health minister said the revelation supports his country's past reluctance to share its avian flu strains with U.S. researchers out of a fear they would not be accessible in developing countries. Under the regulation, vaccines of any type could be denied North Korea, Iran, Cuba, Syria and Sudan on grounds the countries could use them in bioweapons. U.S. health experts questioned about the regulation said they were not aware of the restriction, but said it made no sense because the rule would make it harder to contain an outbreak. (Click here for more
You may also be interested in...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.